Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludwig G Strauss

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|January 27, 2006
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapySophia Koukouraki, Ludwig G Strauss, Vassilios Georgoulias, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2012
Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CTRon Epelbaum, Alex Frenkel, Riad Haddad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 9, 2002
The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesionsAntonia Dimitrakopoulou-Strauss, Ludwig G Strauss, Thomas Heichel, et al.
American Journal of Nuclear Medicine and Molecular Imaging|October 12, 2013
Dynamic PET with (18)F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumorsLudwig G Strauss, Dirk Koczan, Sven Klippel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2010
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysisAntonia Dimitrakopoulou-Strauss, Ludwig G Strauss, Gerlinde Egerer, et al.
Journal of Cancer Research and Clinical Oncology|December 12, 2012
Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysisMaren Bretschi, Caixia Cheng, Hendrik Witt, et al.
Onkologie|March 7, 2008
Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomographyBernd Kasper, Sascha Dietrich, Antonia Dimitrakopoulou-Strauss, et al.
Hellenic Journal of Nuclear Medicine|December 17, 2008
Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomasMarcel Seiz, Antonia Dimitrakopoulou-Strauss, Gerrit A Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
18F-FDG kinetics and gene expression in giant cell tumorsLudwig G Strauss, Antonia Dimitrakopoulou-Strauss, Dirk Koczan, et al.
EJNMMI Research|January 5, 2012
Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell lineCaixia Cheng, Leyun Pan, Antonia Dimitrakopoulou-Strauss, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Nuclear Medicine and Molecular Imaging|January 27, 2006
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapySophia Koukouraki, Ludwig G Strauss, Vassilios Georgoulias, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 21, 2012
Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CTRon Epelbaum, Alex Frenkel, Riad Haddad, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 9, 2002
The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesionsAntonia Dimitrakopoulou-Strauss, Ludwig G Strauss, Thomas Heichel, et al.
American Journal of Nuclear Medicine and Molecular Imaging|October 12, 2013
Dynamic PET with (18)F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumorsLudwig G Strauss, Dirk Koczan, Sven Klippel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2010
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysisAntonia Dimitrakopoulou-Strauss, Ludwig G Strauss, Gerlinde Egerer, et al.
Journal of Cancer Research and Clinical Oncology|December 12, 2012
Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysisMaren Bretschi, Caixia Cheng, Hendrik Witt, et al.
Onkologie|March 7, 2008
Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomographyBernd Kasper, Sascha Dietrich, Antonia Dimitrakopoulou-Strauss, et al.
Hellenic Journal of Nuclear Medicine|December 17, 2008
Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomasMarcel Seiz, Antonia Dimitrakopoulou-Strauss, Gerrit A Schubert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2004
18F-FDG kinetics and gene expression in giant cell tumorsLudwig G Strauss, Antonia Dimitrakopoulou-Strauss, Dirk Koczan, et al.
EJNMMI Research|January 5, 2012
Comparison between 68Ga-bombesin (68Ga-BZH3) and the cRGD tetramer 68Ga-RGD4 studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell lineCaixia Cheng, Leyun Pan, Antonia Dimitrakopoulou-Strauss, et al.
Pageof 7